Startup Microlin Files for $25M IPO to Advance microRNA Drug, Diagnostic Pipeline | GenomeWeb

Just months after securing the rights to its core intellectual property, microRNA shop Microlin Bio has filed with US regulators for a $25 million initial public offering.

According to a filing with the US Securities and Exchange Commission, Microlin will primarily used the proceeds of the offering to fund its pipeline, as well as to pay back the money it agreed to pay to pick up the rights to its IP.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.